Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review.


Journal

Autoimmunity reviews
ISSN: 1873-0183
Titre abrégé: Autoimmun Rev
Pays: Netherlands
ID NLM: 101128967

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 14 04 2020
accepted: 15 04 2020
pubmed: 8 5 2020
medline: 11 6 2020
entrez: 8 5 2020
Statut: ppublish

Résumé

Severe Acute Respiratory Syndrome related to Coronavirus-2 (SARS-CoV-2), coronavirus disease-2019 (COVID-19) may cause severe illness in 20% of patients. This may be in part due to an uncontrolled immune-response to SARS-CoV-2 infection triggering a systemic hyperinflammatory response, the so-called "cytokine storm". The reduction of this inflammatory immune-response could be considered as a potential therapeutic target against severe COVID-19. The relationship between inflammation and clot activation must also be considered. Furthermore, we must keep in mind that currently, no specific antiviral treatment is available for SARS-CoV-2. While moderate-severe forms need in-hospital surveillance plus antivirals and/or hydroxychloroquine; in severe and life-threating subsets a high intensity anti-inflammatory and immunomodulatory therapy could be a therapeutic option. However, right data on the effectiveness of different immunomodulating drugs are scarce. Herein, we discuss the pathogenesis and the possible role played by drugs such as: antimalarials, anti-IL6, anti-IL-1, calcineurin and JAK inhibitors, corticosteroids, immunoglobulins, heparins, angiotensin-converting enzyme agonists and statins in severe COVID-19.

Identifiants

pubmed: 32376394
pii: S1568-9972(20)30131-2
doi: 10.1016/j.autrev.2020.102569
pmc: PMC7252146
pii:
doi:

Substances chimiques

Angiotensin-Converting Enzyme Inhibitors 0
Anticoagulants 0
Antimalarials 0
Antiviral Agents 0
Cytokines 0
Glucocorticoids 0
Hydroxymethylglutaryl-CoA Reductase Inhibitors 0
Immunoglobulins, Intravenous 0
Janus Kinases EC 2.7.10.2

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

102569

Informations de copyright

Copyright © 2020. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The author also state that they do not have any commercial or any other type of interest that may have influenced the drawing up and the results of this paper.

Références

Immunol Res. 2014 Dec;60(2-3):177-83
pubmed: 25388964
Eur J Rheumatol. 2019 Dec 03;:1-8
pubmed: 31804174
Int Immunol. 2017 Dec 30;29(11):491-498
pubmed: 28666326
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975
pubmed: 32350134
Ann Vasc Surg. 2007 Jan;21(1):50-5
pubmed: 17349336
Annu Rev Pathol. 2018 Jan 24;13:27-49
pubmed: 28934563
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
Nat Med. 2004 Nov;10(11):1222-6
pubmed: 15489858
Travel Med Infect Dis. 2020 Feb 27;:101606
pubmed: 32114074
N Engl J Med. 2006 Sep 7;355(10):1018-28
pubmed: 16908486
N Engl J Med. 2020 Apr 10;:
pubmed: 32275812
J Infect Dis. 2015 Feb 15;211(4):661-2
pubmed: 25160984
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Intensive Care Med. 2020 May;46(5):854-887
pubmed: 32222812
Thromb Res. 2003 Jan 1;109(1):1-11
pubmed: 12679126
Trends Endocrinol Metab. 2018 Jan;29(1):42-54
pubmed: 29162310
Postgrad Med J. 2005 Jun;81(956):e3
pubmed: 15937197
Life Sci. 2006 Apr 4;78(19):2166-71
pubmed: 16303146
Lupus. 2012 Jun;21(7):784-6
pubmed: 22635233
J Immunol. 2010 Nov 1;185(9):5628-36
pubmed: 20870944
Cell Discov. 2020 Feb 24;6:11
pubmed: 32133153
Lancet. 1986 Jul 26;2(8500):217-8
pubmed: 2873457
Lancet. 2020 Feb 29;395(10225):683-684
pubmed: 32122468
Ann Hematol. 2019 Jan;98(1):67-72
pubmed: 30255313
Pathobiology. 1996;64(5):255-61
pubmed: 9068008
Curr Opin Hematol. 2011 Sep;18(5):361-5
pubmed: 21730831
Eur J Clin Microbiol Infect Dis. 2005 Sep;24(9):583-91
pubmed: 16172857
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Antimicrob Agents Chemother. 2020 May 21;64(6):
pubmed: 32205349
Lancet. 2020 Feb 15;395(10223):e30-e31
pubmed: 32032529
Nature. 2003 Nov 27;426(6965):450-4
pubmed: 14647384
Eur Heart J. 2020 May 14;41(19):1858
pubmed: 32227120
J Immunol. 1988 Mar 1;140(5):1660-4
pubmed: 3126233
J Infect Dis. 2015 Jan 1;211(1):80-90
pubmed: 25030060
Microbes Infect. 2020 Mar;22(2):72-73
pubmed: 32092539
J Nucl Med. 2020 May;61(5):630-631
pubmed: 32238427
Lupus. 2006;15(5):268-75
pubmed: 16761500
J Antimicrob Chemother. 2020 Mar 20;:
pubmed: 32196083
Am J Respir Crit Care Med. 2009 Jun 15;179(12):1107-14
pubmed: 19324974
Intern Med. 2018 Dec 1;57(23):3473-3478
pubmed: 29984753
Int J Antimicrob Agents. 2020 Mar 20;:105949
pubmed: 32205204
Chest. 2013 Aug;144(2):464-473
pubmed: 23450336
Clin Exp Rheumatol. 2003 Mar-Apr;21(2):241-8
pubmed: 12747285
Front Oncol. 2019 Nov 07;9:1186
pubmed: 31788449
Lancet. 2013 Sep 14;382(9896):984-94
pubmed: 23642914
Hematology Am Soc Hematol Educ Program. 2015;2015:183-9
pubmed: 26637719
N Engl J Med. 2005 Oct 20;353(16):1711-23
pubmed: 16236742
Open Forum Infect Dis. 2020 Mar 21;7(3):ofaa102
pubmed: 32258207
Emerg Microbes Infect. 2020 Dec;9(1):687-690
pubmed: 32208840
Ann Intern Med. 2020 May 5;172(9):629-632
pubmed: 32163542
Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):797-801
pubmed: 15642942
Drugs. 2017 Nov;77(17):1865-1879
pubmed: 29094311
Int J Hypertens. 2012;2012:307315
pubmed: 22121476
JAMA. 2020 Mar 27;:
pubmed: 32219428
Pediatr Rheumatol Online J. 2019 Feb 14;17(1):7
pubmed: 30764840
Nature. 2005 Jul 7;436(7047):112-6
pubmed: 16001071
Semin Immunopathol. 2017 Jul;39(5):529-539
pubmed: 28466096
mBio. 2020 Mar 20;11(2):
pubmed: 32198163
Cytokine. 2015 Oct;75(2):216-21
pubmed: 25541434
Cochrane Database Syst Rev. 2019 Jul 23;7:CD004477
pubmed: 31334568
Nat Rev Immunol. 2002 Jan;2(1):37-45
pubmed: 11905836
Thromb Res. 2010 May;125(5):e240-5
pubmed: 20035973
Emerg Infect Dis. 2016 Sep;22(9):1554-61
pubmed: 27532807
Lupus. 2013 Nov;22(13):1327-35
pubmed: 24036580
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Crit Care Med. 2016 Feb;44(2):275-81
pubmed: 26584195
Curr Opin Rheumatol. 2020 May;32(3):201-207
pubmed: 32168069
Crit Care. 2020 Mar 16;24(1):91
pubmed: 32178711
Autoimmun Rev. 2020 Jun;19(6):102537
pubmed: 32251717
Autoimmun Rev. 2020 Jun;19(6):102536
pubmed: 32251718
Int J Antimicrob Agents. 2020 Apr;55(4):105932
pubmed: 32145363
Clin Sci (Lond). 2015 Jul;129(2):93-105
pubmed: 25927679
Lancet. 2020 Feb 15;395(10223):473-475
pubmed: 32043983
Nat Rev Dis Primers. 2019 Mar 14;5(1):18
pubmed: 30872586
Infect Dis Rep. 2020 Mar 16;12(1):8543
pubmed: 32218915
BMJ. 2018 Aug 10;362:k3284
pubmed: 30097460
Zhonghua Xue Ye Xue Za Zhi. 2020 Mar 14;41(3):185-191
pubmed: 32133825
Eur J Immunol. 2010 Jul;40(7):1830-5
pubmed: 20583029
Lupus. 2006;15(3):183-90
pubmed: 16634374
Front Immunol. 2019 Feb 01;10:119
pubmed: 30774631
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112
Shock. 2009 May;31(5):500-6
pubmed: 18827741
J Clin Rheumatol. 2010 Mar;16(2):61-3
pubmed: 20216125
J Crit Care. 2020 Jun;57:279-283
pubmed: 32173110
J Biol Chem. 2000 Oct 27;275(43):33238-43
pubmed: 10924499
PLoS Pathog. 2011 Oct;7(10):e1002331
pubmed: 22046132
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
N Engl J Med. 2020 Apr 23;382(17):e38
pubmed: 32268022
Expert Rev Clin Pharmacol. 2017 Oct;10(10):1109-1118
pubmed: 28691537
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Autoimmun Rev. 2020 Jun;19(6):102538
pubmed: 32268212
J Med Virol. 2020 Feb 28;:
pubmed: 32108352
Lancet. 2003 May 24;361(9371):1773-8
pubmed: 12781536
Science. 2012 Feb 24;335(6071):936-41
pubmed: 22363001
Neurocrit Care. 2015 Oct;23(2):259-61
pubmed: 25678454
Expert Rev Clin Immunol. 2015;11(9):1043-53
pubmed: 26082353
Obstet Gynecol Surv. 2018 Jan;73(1):40-55
pubmed: 29368790
Lancet. 2020 Apr 4;395(10230):1111
pubmed: 32220278
Lancet. 2003 Apr 19;361(9366):1319-25
pubmed: 12711465
Antimicrob Agents Chemother. 2020 Apr 21;64(5):
pubmed: 32152082
Nature. 1994 Nov 24;372(6504):363-5
pubmed: 7969495
J Biol Regul Homeost Agents. 2020 Mar 14;34(2):
pubmed: 32171193

Auteurs

Jaume Alijotas-Reig (J)

Systemic Autoimmune Diseases Unit, Department of Internal Medicine-1, Vall d'Hebron University Hospital, Barcelona, Spain; Systemic Autoimmune Research Unit, Vall d'Hebron Reseacrh Institute, Spain; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address: jalijotas@vhebron.net.

Enrique Esteve-Valverde (E)

Department of Internal Medicine, Althaia Network Health, Manresa, Barcelona, Spain; Universitat Central de Catalunya, Spain.

Cristina Belizna (C)

Vascular and Coagulation Department, University Hospital Angers, Angers, France; UMR CNRS 6015, Angers, France; INSERM U1083, Angers, France.

Albert Selva-O'Callaghan (A)

Systemic Autoimmune Diseases Unit, Department of Internal Medicine-1, Vall d'Hebron University Hospital, Barcelona, Spain; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.

Josep Pardos-Gea (J)

Systemic Autoimmune Diseases Unit, Department of Internal Medicine-1, Vall d'Hebron University Hospital, Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain.

Angela Quintana (A)

Systemic Autoimmune Research Unit, Vall d'Hebron Research Institute, Barcelona, Spain.

Arsene Mekinian (A)

Service de Médecine Interne, Centre de référence AO Bradykiniques et compétence Maladies Auto-immunes FAI2R, Hôpital Saint Antoine Hôpitaux Universitaires de l'Est Parisien, Professeur des Universités-Praticien Hospitalier Sorbonne Université, France.

Ariadna Anunciacion-Llunell (A)

Systemic Autoimmune Research Unit, Vall d'Hebron Research Institute, Barcelona, Spain.

Francesc Miró-Mur (F)

Systemic Autoimmune Research Unit, Vall d'Hebron Research Institute, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH